Analytical Data
-
基因名
CD66d/CEACAM3
- Application
-
别名
Carcinoembryonic antigen CGM1 CD_antigen: CD66d
-
种属
Human
-
表达系统
E. coli
-
标签
N- His-SUMO
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P40198
-
表达区间
35-155aa
-
分子量
29.1 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD66d, also known as CEACAM3, is a member of the carcinoembryonic antigen (CEA) family of glycoproteins, primarily expressed on the surface of immune cells, particularly neutrophils and some T cells. This protein plays a critical role in the immune response by mediating cell adhesion and facilitating intercellular communication. Research has indicated that CD66d/CEACAM3 is involved in various immune-related processes, including the regulation of inflammation, the modulation of immune signaling pathways, and the potential recognition of pathogens. Its ability to interact with other immune receptors suggests a significant role in the innate immune response, particularly in recognizing and responding to bacterial infections. Given its potential implications in immunotherapy and vaccine development, CD66d/CEACAM3 has become a target of interest in various biomedical research areas. Recombinant proteins of CD66d/CEACAM3 are being developed for both basic research purposes and therapeutic applications, allowing for a deeper understanding of its functional roles and mechanisms in immune regulation. These studies aim to elucidate its contributions to immune defense and uncover its potential as a biomarker or therapeutic target in diseases where immune dysregulation is a factor, including infections and cancer. Understanding the structural and functional aspects of the CD66d/CEACAM3 protein could pave the way for innovative strategies in enhancing immune responses, thereby contributing to improved health outcomes.
